证券代码：688513 证券简称：苑东生物 公告编号：2026-002 成都苑东生物制药股份有限公司 关于自愿披露 EP-0226 片 I 期临床试验完成首例受试 者给药的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 成都苑东生物制药股份有限公司（以下简称"公司"）与中国科学院上海药物 研究所、中科中山药物创新研究院共同研发的 1 类化学创新药 EP-0226 片正在开 展用于治疗神经病理性疼痛的 I 期临床试验，于近日完成首例受试者给药。现将 相关情况公告如下： 一、 EP-0226 片的基本情况 EP-0226 片拟用于治疗神经病理性疼痛，是一种新型的钙离子通道（Cav2.2） 调节剂，其作用机制是通过与钙离子通道α2δ亚基结合，减少神经元钙离子内流， 从而减少谷氨酸盐、去甲肾上腺素等兴奋性神经递质的释放，进而有效控制神经 病理性疼痛。 特此公告。 成都苑东生物制药股份有限公司 本品作为新一代的钙离子通道调节剂，与中枢神经系统组织中的α2δ亚基有 高度亲和力。临床前研究表明，EP-0226 片在靶点选择性、体内 ...

"我们这支团队，是伴随着中国通信产业从3G到5G的反战过程一起成长起来的。"元测信息创始人王奥博向天虎科技表示。 元测信息核心团队 时间拉回到20年前，当中国自主知识产权的3G通信标准TD-SCDMA在2004年准备迈向产业化时，市场上几乎没有支持这一标准的通信测试仪器。面对着 被国外企业"卡脖子"的困境，来自北京邮电大学张平院士的团队接下了这项"从零开始"的攻关任务，并在2006年推出了全球首台TD-SCDMA终端综测仪， 填补了产业空白。那段科研攻关经历，不仅为TD-SCDMA网络的商用铺平了道路，也造就了一支出身北京邮电大学的国内顶尖通信测试团队，核心成员 即包括了王奥博、姜军、唐恬、陈杰等元测信息公司的创始班底。 这段渊源，也形成了元测信息迄今与北京邮电大学网络与交换技术国家重点实验室、中关村泛联移动通信技术创新应用研究院等顶尖科研单位的紧密合 作。同时元测信息还邀请到了以院士为首的众多产业技术专家，为公司"以技术为第一竞争力、以前瞻握未来主动权"的发展理念指航把舵。 一个源自北京的创业团队，何以在落地成都不足两年的时间内，便吸引到国内知名硬科技投资机构的密集关注？近期创新工场二次增资，深创投最新进 ...

Group 1 - The core viewpoint is that the competition for space resources is accelerating, leading to rapid development in China's commercial space sector, with over 250,000 satellite applications submitted and a projected global space market exceeding $800 billion by 2030 [1][3] Group 2 - The deployment of satellites in the U.S. is significantly ahead, with SpaceX leading the way; by the end of 2025, SpaceX is expected to have deployed over 9,000 satellites, accounting for about 60% of the global total [2] - China's actual satellite deployment is notably lower than that of the U.S., with a strong demand for satellite launches; policies are being implemented to support the acceleration of space development [2] - The global commercial space market is projected to reach $6.13 trillion by 2024, with commercial space accounting for approximately $4.8 trillion; by 2030, the market is expected to grow to $8 trillion, with a CAGR of about 10% from 2025 to 2030 [3]

Core Viewpoint - Hisense Home Appliances has made significant investments in trust financial products, totaling over 5.5 billion yuan, indicating a strategic move to enhance the efficiency of idle funds and increase cash asset returns [1][2]. Group 1: Company Actions - Hisense Home Appliances has announced three purchases of trust financial products since December 20, 2025, involving trust companies such as Jingu Trust, Huaneng Trust, and Zhongcai Trust, with a total investment exceeding 5.5 billion yuan [1]. - The company invested 1.815 billion yuan in Huaneng Trust products between July 16, 2025, and January 20, 2026, signing 10 related agreements [1]. - Hisense's subsidiary also invested 1.855 billion yuan in six products from Zhongcai Trust and 1.892 billion yuan in products from Jingu Trust during the same period [1]. Group 2: Industry Performance - The three trust companies involved reported strong financial performance in 2025, with Zhongcai Trust achieving 1.409 billion yuan in revenue and 653 million yuan in net profit, Huaneng Trust with 2.815 billion yuan in revenue and 1.260 billion yuan in net profit, and Jingu Trust with 1.562 billion yuan in revenue and 823 million yuan in net profit [2]. - Hisense Home Appliances accounted for 68.3% of the total trust financial product purchases by listed companies in 2025, with a total subscription amount of 17.854 billion yuan [2][3]. Group 3: Market Trends - In 2025, A-share listed companies collectively subscribed to trust products worth 26.123 billion yuan, an increase from 22.909 billion yuan in 2024, indicating a growing trend in utilizing trust financial products to manage idle funds [3]. - Companies across various sectors, including manufacturing and technology, have shown different preferences in trust product selection, with tech firms opting for short-term products for liquidity, while manufacturing firms like Hisense prefer fixed-income products for stable returns [3]. Group 4: Regulatory Environment - The trust industry has seen a shift towards standardized asset management, with non-standard assets becoming a secondary investment method, reflecting a regulatory push for better disclosure and risk management [5]. - The 2025 revised Trust Company Management Measures require trust companies to establish robust information disclosure systems, enhancing the quality of disclosures and compliance [5].

Core Viewpoint - Yuan Dong Bio's wholly-owned subsidiary, Shuo De Pharmaceutical, has received approval from the National Medical Products Administration for the drug registration certificate of Chloral Hydrate Syrup, specifically designed for children [1] Group 1: Product Details - Chloral Hydrate Syrup is intended for sedation and hypnosis in children prior to examinations and procedures [1] - The syrup offers advantages such as no need for dilution, precise dosage control, and a child-friendly taste [1] Group 2: Company Impact - The approval of this drug enriches the company's product pipeline in the anesthesia and analgesia sector [1] - The product has not yet been commercialized, so it will not have a significant impact on the company's recent performance [1]

Group 1 - Huibo Yuntong plans to acquire 65.47% of Baode Computer System shares through a share issuance and has received acceptance from the Shenzhen Stock Exchange for its application [1] - Mingyang Smart Energy intends to purchase 100% of Dehua Chip's equity through a combination of share issuance and cash payment, with stock resuming trading on January 23, 2026 [2] - Sanhua Intelligent Control's controlling shareholder and board members plan to reduce their holdings by up to 0.2425% of the company's shares [3] Group 2 - Wuchan Jinlun's shareholder plans to reduce holdings by up to 3% of the company's total shares [4] - Chengdu Road and Bridge expects a net loss of 65 million to 97.5 million yuan for 2025, compared to a loss of 92.17 million yuan in the previous year [5] - Guoxin Technology anticipates a net loss of 238 million yuan for 2025, an increase in loss of 56.97 million yuan compared to the previous year [6] Group 3 - Taiankang's subsidiary received approval for a clinical trial of CKBA ointment for treating vitiligo in children aged 2-12 [7] - Boyun New Materials' shareholder plans to reduce holdings by up to 1% of the company's total shares [8] - *ST Shengwu has terminated its major asset restructuring plan and expects a net profit of 28.5 million to 32.5 million yuan for 2025, compared to a loss of 19.84 million yuan in the previous year [9] Group 4 - Junchen Technology's shareholder plans to reduce holdings by up to 2.94% of the company's shares [10] - Haiguang Information's shareholder plans to reduce holdings by up to 0.5% of the company's shares [11] - ST Juewei expects a net loss of 160 million to 220 million yuan for 2025, compared to a profit of 227 million yuan in the previous year [12] Group 5 - Nanjing Bank reported total assets exceeding 3 trillion yuan by the end of 2025, with a revenue of 55.54 billion yuan, up 10.48% year-on-year [13] - Haitan Ruisheng's shareholders plan to reduce holdings by up to 5% of the company's shares [14] - Zhaoyi Innovation expects a net profit of approximately 1.61 billion yuan for 2025, a year-on-year increase of about 46% [15] Group 6 - Xiangrikui is discussing a repayment arrangement for a deposit of 40 million yuan with Shanghai Xipu Technology [16] - Yinglian Co. signed a strategic agreement with LG Chem to develop new polymer materials for lithium battery applications [17] - Yingfang Micro expects a net loss of 69 million to 97 million yuan for 2025, compared to a loss of 61.97 million yuan in the previous year [18] Group 7 - Heshun Electric's shareholders plan to reduce holdings by up to 3.5% of the company's shares [20] - Guanghua Technology expects a net profit of 85 million to 120 million yuan for 2025, reversing a loss of 205 million yuan in the previous year [21] - Ruichuang Weina anticipates a net profit of approximately 1.1 billion yuan for 2025, a year-on-year increase of about 93% [22] Group 8 - Huatu Mountain Ding's shareholder plans to reduce holdings by up to 3% of the company's shares [23] - Yinfeng Storage's subsidiary won two procurement projects with a total value of approximately 1.23 billion yuan [24] - Hengyi Petrochemical plans to repurchase shares worth 500 million to 1 billion yuan for employee stock ownership plans [25] Group 9 - Mengcao Ecology's controlling shareholder plans to reduce holdings by up to 3% of the company's shares [26] - Tefa Service's shareholder plans to reduce holdings by up to 3% of the company's shares [27] - Green Alliance Technology's shareholders plan to reduce holdings by up to 4% of the company's shares [28] Group 10 - Yunyi Electric plans to repurchase shares worth 100 million to 150 million yuan for employee stock ownership plans [29] - Dongpeng Beverage plans to invest 1.1 billion yuan in a new production base in Chengdu [30] - Zhongyuan Co. expects a net profit of 139 million to 158 million yuan for 2025, a year-on-year increase of 80% to 105% [31] Group 11 - Qiangyi Co. expects a net profit of 368 million to 399 million yuan for 2025, a year-on-year increase of 57.87% to 71.17% [32] - Guochuang High-tech anticipates a net profit of 16 million to 24 million yuan for 2025, reversing a loss of 49.1 million yuan in the previous year [33] - Yuandong Bio received a drug registration certificate for a pediatric medication [34] Group 12 - Liya Technology expects a net profit of 300 million to 380 million yuan for 2025, reversing a loss of 889 million yuan in the previous year [35] - Dongfeng Co. anticipates a net loss of 390 million to 480 million yuan for 2025, compared to a profit of 29.16 million yuan in the previous year [36] - Huaming Equipment reported a 15.29% year-on-year increase in net profit for 2025 [37] Group 13 - Botong Integrated expects a net profit of 17.19 million to 25.78 million yuan for 2025, reversing a loss from the previous year [38] - Qingsong Co. anticipates a net profit of 130 million to 165 million yuan for 2025, a year-on-year increase of 137.73% to 201.74% [39] - Ruihua Tai's shareholder plans to reduce holdings by up to 3% of the company's shares [41]

Policy Developments - The Ministry of Commerce and nine other departments issued an opinion to promote the high-quality development of the pharmaceutical retail industry, proposing 18 specific measures focused on improving pharmaceutical services and emergency supply guarantees [1] - The opinion emphasizes the development of smart regulation, including accurate collection and verification of drug traceability codes and uploading to a national medical insurance information platform [1] - A dynamic regulatory model based on risk levels and credit evaluations will be implemented, optimizing inspection frequencies for low-risk enterprises and exploring non-on-site supervision methods like AI video inspections [1] Drug Approval - Yuandong Bio's subsidiary Shod Pharmaceutical received a drug registration certificate for chloral hydrate syrup, aimed at sedation and hypnosis for children, marking the company's first approved Class 2 modified new drug [2] - West Point Pharmaceutical announced the approval of glucosamine sulfate capsules for primary or secondary osteoarthritis, enhancing its product line but facing sales uncertainties due to industry policies and procurement factors [3] Capital Market - OpenEvidence, a medical AI startup, completed a $250 million Series D financing round, achieving a valuation of $12 billion, with total financing nearing $700 million [4] - West Point Pharmaceutical plans to repurchase shares worth between 25 million and 50 million RMB, with a maximum repurchase price of 42.00 RMB per share, representing 0.78% to 1.56% of its total A-share capital [5] Industry Developments - Baichuan Intelligent launched the evidence-enhanced medical model M3 Plus, reducing hallucination rates to 2.6%, the lowest globally, and introduced the "evidence anchoring" technology to link generated medical conclusions to original research [6][7] - Sinovac's inactivated hepatitis A vaccine has secured a two-year exclusive bid in Oman, with over 130 million doses supplied globally, making it one of the most widely used hepatitis A vaccines [8] Public Opinion Alerts - Yiju Medical announced the resignation of non-executive director Dr. Zhou Yi, effective January 22, 2026, to focus on other business commitments [9]

水合氯醛作为临床应用成熟的镇静催眠药物，其安全性与有效性已得到广泛验证，被中华医学会麻醉学 分会、美国急诊医师学院等国内外众多权威学术机构推荐为儿童镇静催眠常用药物或一线用药。国家药 监局官网显示，国内现有3款水合氯醛口服制剂获得批准，为特丰制药的水合氯醛/糖浆组合包装，以及 成都倍特得诺药业、海南鹏康药业的水合氯醛糖浆。 公司全资子公司硕德药业的水合氯醛糖浆是公司首款获得批准的2类改良型新药。该药品的获批，标志 着公司该产品符合药品注册的有关要求，进一步丰富了公司麻醉镇痛领域产品管线，对公司经营发展具 有一定的积极作用。 格隆汇1月22日丨苑东生物(688513.SH)公布，公司全资子公司成都硕德药业有限公司于近日收到国家药 监局核准签发的《药品注册证书》。药品名称：水合氯醛糖浆，药品注册标准编号：YBH26472025。 水合氯醛糖浆活性成份为水合氯醛，是一款针对儿科临床用药痛点设计的专用糖浆剂型，适应症为儿童 检查、操作前的镇静、催眠，属于《国家基本医疗保险、工伤保险和生育保险药品目录（2025年）》乙 类品种。与已上市的水合氯醛/糖浆组合包装相比，本品无需稀释即可直接给药，能精准调控给药剂 量，且专为 ...

规格：10ml:1.0g 注册分类：化学药品 2.2 类 证券代码：688513 证券简称：苑东生物 公告编号：2026-001 成都苑东生物制药股份有限公司 关于自愿披露 2 类改良型新药水合氯醛糖浆获得 药品注册证书的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈 述或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 成都苑东生物制药股份有限公司（以下简称"公司"） 全资子公司成都硕德 药业有限公司（以下简称"硕德药业"）于近日收到国家药品监督管理局（以下 简称"国家药监局"）核准签发的《药品注册证书》，现将相关情况公告如下： 一、药品基本情况 药品名称：水合氯醛糖浆 剂型：糖浆剂 药品有效期：12 个月 上市许可持有人：成都硕德药业有限公司 生产企业：成都硕德药业有限公司 药品注册标准编号：YBH26472025 受理号：CXHS2300053 证书编号：2026S00061 药品批准文号：国药准字 H20260003 审批结论：根据《中华人民共和国药品管理法》及有关规定，经审查，本 品符合药品注册的有关要求，批准注册，发给药品注册证书。质量标准、说明 1 米内网 ...

Core Viewpoint - The approval of the drug "Hydrated Chloral Syrup" by the National Medical Products Administration marks a significant advancement for the company in the pediatric clinical medication sector, addressing specific needs for sedation and hypnosis in children [1][2] Group 1: Product Details - The active ingredient of Hydrated Chloral Syrup is hydrated chloral, designed specifically for pediatric use, with indications for sedation and hypnosis before examinations and procedures [1] - This product is classified as a Category B drug in the National Basic Medical Insurance, Work Injury Insurance, and Maternity Insurance Drug Catalog (2025) [1] - Unlike existing hydrated chloral/syrup combination products, this syrup does not require dilution for administration, allowing for precise dosage control and improved palatability for children [1] Group 2: Market Context - Hydrated chloral is a well-established sedative and hypnotic drug, with its safety and efficacy widely validated and recommended by various authoritative medical institutions [1] - Currently, there are three approved oral formulations of hydrated chloral in China, including those from other pharmaceutical companies [1] Group 3: Company Impact - The approval of Hydrated Chloral Syrup represents the company's first approved Category II modified new drug, enhancing its product pipeline in the anesthesia and analgesia field [2] - This development is expected to have a positive impact on the company's operational growth [2]